Piramal Pharma Solutions, a global leader in contract development and manufacturing and part of Piramal Pharma Ltd., has entered into a strategic partnership with IntoCell Inc., a Korean biotech company recognized for its innovative antibody-drug conjugate linker and payload technologies. The agreement is non-exclusive and non-binding, allowing IntoCell to explore licensing opportunities for its proprietary drug-linker platforms with Piramal’s clients. In return, Piramal will offer full contract research, development, and manufacturing services for bioconjugates, including antibody-drug conjugates (ADCs), to IntoCell and its clients.
Health Technology Insights: Fractal Earns AWS Generative AI Consulting Competency
This collaboration enhances Piramal’s existing capabilities in payload-linker and bioconjugation, enabling the company to offer a broader range of payload-linkers and speed up the development of bioconjugates. IntoCell’s technologies, such as the OHPAS linker, Duocarmycin-based OHPAS payload, Nexatecan-based OHPAS payload, and iso-Nexatecan GGFG payload, form the basis of the licensing agreement. Together, the companies aim to make ADC development faster, more efficient, and more flexible.
Health Technology Insights: Investors Eye AI Imaging Firms in Growing Breast Cancer Market
The partnership also supports ADCelerate, Piramal’s integrated approach to bioconjugate development and manufacturing. By using IntoCell’s expertise and technologies, Piramal can simplify the process from early concept to clinical testing, helping clients get advanced bioconjugate solutions more quickly and efficiently.
Tae Kyo Park, CEO of IntoCell Inc., said, “We are excited to work with Piramal Pharma Solutions. Combining our strengths will create a partnership that benefits both companies and supports innovation in ADC technology.”
Peter DeYoung, CEO of Piramal Global Pharma, added, “This collaboration brings together IntoCell’s cutting-edge drug-linker technologies and our extensive experience in bioconjugates. It positions us as a trusted partner for clients developing next-generation ADCs and helps us advance patient care around the world.”
Health Technology Insights: Lindus Health Names Heather Davis VP of US Clinical Operations
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
